In the United States, Johnson & Johnson has achieved a significant milestone by obtaining 'de novo' approval from the US Food and Drug Administration for its innovative surgical robot, Ottava. This system is touted as the world's first table-integrated soft tissue robotic surgical system, designed specifically for various general surgery procedures within the upper abdomen. The approval marks a pivotal moment in the evolution of surgical robotics, as it aims to enhance the efficiency and effectiveness of surgical operations.
Ottava is engineered to perform multiple procedures, including gastric bypasses, gastrectomies, appendectomies, and hiatal hernia repairs. One of the standout features of this robotic system is its compact design, which allows its four robotic arms to occupy up to 50% less space compared to traditional boom- and cart-mounted solutions. This space-saving design is particularly beneficial in operating theatres, where space is often at a premium, enabling a more organized and efficient surgical environment.
Moreover, the system is equipped with advanced programming capabilities that facilitate the setup and breakdown of the operating theatre, as well as the manipulation of patient positioning during procedures. This technological advancement is complemented by a curated range of surgical tools and a digital ecosystem that supports surgeons in their work. Tim Schmid, the executive vice-president and worldwide chairman of medtech at Johnson & Johnson, emphasized that Ottava represents a pioneering step in surgical robotics, aiming to deliver improved surgical care informed by technology and clinical insights.
The commercial launch of Ottava will initially target select customers in the United States, with plans to expand into other use cases and regulatory jurisdictions in the future. Hani Abouhalka, the group chair for surgery and medtech at Johnson & Johnson, highlighted the system's potential to transform surgical workflows and architecture, ultimately delivering clinical and economic benefits as the future of surgery unfolds. This approval not only signifies a leap forward in surgical technology but also sets the stage for a new era in surgical care, driven by data and digital innovation.
